Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
Joshua J. Meeks, Peter C. Black, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Syed A. Hussain, Matthew I. Milowsky, Gary D. Steinberg, Robert S. Svatek, Jonathan E. Rosenberg
Topics & Concepts
MedicineMetastatic Urothelial CarcinomaNivolumabCystectomyOncologyInternal medicinePembrolizumabBladder cancerClinical endpointClinical trialCancerImmunotherapyUrothelial carcinomaBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis